Down the hatch

Arvinas LLC believes its solution for oral delivery of its Proteolysis Targeting Chimeras (PROTACs) will give it a leg up over others in the space, allowing it to both expand its pipeline and broaden the reach of its therapeutics. At this year’s meeting of the American Association for Cancer Research (AACR), the company presented preclinical data showing its lead compound can reach oral bioavailabilities of 30-90% across four species.

"We clearly see the ability to get oral bioavailability as a significant competitive advantage over other companies that are moving into this space," said CSO John Houston. ...